Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems
- 616 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems
About This Book
Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models.
The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development.
- Explores recent perspectives and challenges regarding the management and diagnosis of chronic respiratory diseases
- Provides insights into how advanced drug delivery systems can be effectively formulated and delivered for the management of various pulmonary diseases
- Includes the most recent information on diagnostic methods and treatment strategies using controlled drug delivery systems (including nanotechnology)
Frequently asked questions
Information
Table of contents
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Editors biography
- Chapter 1: Chronic respiratory diseases: An introduction and need for novel drug delivery approaches
- Chapter 2: Drug delivery of respiratory medicines in practice
- Chapter 3: Advanced drug delivery systems for respiratory diseases
- Chapter 4: Novel drug delivery systems and significance in respiratory diseases
- Chapter 5: Use of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis
- Chapter 6: Targeting biofilms in chronic respiratory infections using drug delivery systems
- Chapter 7: Absorption enhancement of macromolecule-administered intrapulmonary
- Chapter 8: In silico analysis of drug delivery in respiratory disease
- Chapter 9: Concepts of nanotechnology in nanomedicine: From discovery to applications
- Chapter 10: Advancement in translational respiratory research using nanotechnology
- Chapter 11: Nanoparticle-based macromolecule drug delivery to lungs
- Chapter 12: Formulation and role of polymeric and inorganic nanoparticles in respiratory diseases
- Chapter 13: Inhalable hybrid nanocarriers for respiratory disorders
- Chapter 14: Functionalized nanoparticles in pulmonary disease diagnosis
- Chapter 15: Drug delivery system in pulmonary disease: Role of microparticles
- Chapter 16: Microparticulate drug delivery systems for targeting respiratory diseases
- Chapter 17: Porous particulate platforms for enhanced pulmonary delivery of bioactives
- Chapter 18: Liposomes in the treatment of chronic respiratory conditions
- Chapter 19: Theranostic drug delivery systems for targeted therapy of lung diseases
- Chapter 20: Targeted polymeric micellar systems for respiratory diseases
- Chapter 21: Hydrogels for pulmonary drug delivery
- Chapter 22: Mucoadhesive drug delivery systems in respiratory diseases
- Chapter 23: Targeting lung cancer using advanced drug delivery systems
- Chapter 24: Plant-based drug delivery systems in respiratory diseases
- Chapter 25: Role of essential oils in respiratory diseases through advanced and nanodrug delivery systems
- Chapter 26: Pharmacokinetics and pharmacodynamics of the advanced drug delivery systems
- Index